Published in Clin Chest Med on October 07, 2011
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res (2013) 1.57
The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas. Cancer Cell (2013) 1.36
Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer (2013) 1.23
VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res (2014) 1.20
Musical patterns for comparative epigenomics. Clin Epigenetics (2015) 1.15
Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol (2013) 1.05
Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene (2012) 1.03
TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 0.99
The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities. J Biol Chem (2013) 0.94
Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Med (2015) 0.91
An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling. PLoS One (2015) 0.82
Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis (2014) 0.81
Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells. Oncogene (2013) 0.81
TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis (2013) 0.81
ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest (2016) 0.81
Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer. Oncotarget (2015) 0.80
Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer. Clin Cancer Res (2014) 0.79
Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol (2014) 0.79
Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Mol Oncol (2014) 0.79
Cooperation of tyrosine kinase receptor TrkB and epidermal growth factor receptor signaling enhances migration and dispersal of lung tumor cells. PLoS One (2014) 0.78
Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC). Int J Clin Exp Pathol (2015) 0.77
The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. J Thorac Dis (2014) 0.77
p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer. J Transl Med (2016) 0.76
miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med (2016) 0.75
Repression of YAP by NCTD disrupts NSCLC progression. Oncotarget (2016) 0.75
Lung cancer in women. Lung Cancer (Auckl) (2012) 0.75
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma. Oncotarget (2016) 0.75
Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. Cancer Biol Med (2016) 0.75
Argyrophilic nucleolar organizer region in MIB-1 positive cells in non-small cell lung cancer: clinicopathological significance and survival. Cancer Biol Med (2014) 0.75
Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. Onco Targets Ther (2015) 0.75
Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. Sci Rep (2016) 0.75
Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma. Oncotarget (2016) 0.75
Elevated expression of STIM1 is involved in lung tumorigenesis. Oncotarget (2016) 0.75
Epiregulin as a therapeutic target in non-small-cell lung cancer. Lung Cancer (Auckl) (2015) 0.75
Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies. Future Sci OA (2016) 0.75
FGFR3 silencing by siRNA inhibits invasion of A549 cells. Oncol Lett (2016) 0.75
Exposure of Human Lung Cells to Tobacco Smoke Condensate Inhibits the Nucleotide Excision Repair Pathway. PLoS One (2016) 0.75
CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling. Oncotarget (2016) 0.75
Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells. PLoS One (2017) 0.75
Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers. Cancer Res (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
DNA methylation patterns and epigenetic memory. Genes Dev (2002) 33.83
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
p53 mutations in human cancers. Science (1991) 31.96
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
The clonal evolution of tumor cell populations. Science (1976) 24.39
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
Lung cancer. N Engl J Med (2008) 13.49
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet (2006) 13.16
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (2007) 12.42
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer (2004) 11.79
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev (2007) 10.15
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
miR-21-mediated tumor growth. Oncogene (2006) 9.90
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 8.17
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res (2004) 7.96
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene (2002) 2.92
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell (2010) 2.50
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol (2007) 2.43
Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol (2005) 2.34
Molecular genetics of lung cancer. Annu Rev Med (2001) 2.25
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer (2006) 2.16
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res (2009) 2.11
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res (2013) 2.09
SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res (2002) 2.09
A Semantic Web management model for integrative biomedical informatics. PLoS One (2008) 2.02
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res (2005) 1.94
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res (2005) 1.93
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A (2007) 1.92
New molecularly targeted therapies for lung cancer. J Clin Invest (2007) 1.86
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther (2009) 1.86
RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res (2004) 1.84
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J (2009) 1.83
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Ann Surg Oncol (2006) 1.79
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer (2007) 1.77
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75
Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res (2002) 1.74
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res (2004) 1.74
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One (2010) 1.69
Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res (2007) 1.68
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation (2006) 1.64
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res (2002) 1.61
Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer (2005) 1.60
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res (2013) 1.57
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res (2006) 1.55
Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Reprod Sci (2007) 1.54
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A (2004) 1.53
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
DNA methylation in health, disease, and cancer. Curr Mol Med (2007) 1.52
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A (2008) 1.51
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res (2010) 1.48
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett (2010) 1.47
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev (2010) 1.46
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res (2013) 1.46
Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene (2002) 1.43
3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol (2005) 1.42
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci U S A (2010) 1.42
Multifocal lung cancers--clonality vs field cancerization and does it matter? J Natl Cancer Inst (2009) 1.41
RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies. Proc Natl Acad Sci U S A (2004) 1.39
Molecular pathogenesis of lung cancer. Annu Rev Physiol (2002) 1.39
Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer (2003) 1.39
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med (2010) 1.38
A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res (2003) 1.36
Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer (2006) 1.35
Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett (2003) 1.34
Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res (2005) 1.34
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res (2010) 1.34
Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene (2003) 1.33
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer (2010) 1.33
Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther (2004) 1.32
Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res (2005) 1.31